LLY

SELL

Eli Lilly and Company

Healthcare · Rank #109 · Analyzed Oct 18, 2026

$1257.03

Current Price

$548.74

Intrinsic Value

-56.3%

Upside/Downside

4/10

Score

4/5

Quality

Analysis Summary

Valuation Consensus0/2 methods agree

Quality Score4/5.0

Framework RatingSELL

Price vs Intrinsic ValueOvervalued by 56.3%

Fair Value Range

Low$178.25

Base (IV)$548.74

High$713.36

Entry Points

Conservative$124.78

Moderate$178.25

Aggressive$384.12

Quality & Moat Breakdown

Return on Equity102.3% → 1.0/1.0

Debt LevelD/E 162 → 0/1.0

Revenue QualityGrowth 31.3%, margin Δ+54.7% +recovery → 1.0/1.0

Moat Strength4.0/5 → 1.0/1.0

Profit Margins33.5% → 1.0/1.0

Methodology

This analysis uses a unified valuation framework combining three methods, Discounted Cash Flow (3-scenario), Earnings Power Value, and Asset Valuation, with a quality scoring overlay. A stock needs 2/3 valuation methods to agree and a quality score ≥ 3.5/5 for a BUY rating.

Learn how this framework works →

This is a personal analysis tool, not financial advice. Do your own research before making investment decisions.